| Dr Reuven Moshenyat, | |
|
2044 Ocean Ave, Suite A3, Brooklyn, NY 11230-7328 | |
| (718) 645-8901 | |
| (718) 645-7970 |
| Full Name | Dr Reuven Moshenyat |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 25 Years |
| Location | 2044 Ocean Ave, Brooklyn, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598719585 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 235361 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maimonides Medical Center | Brooklyn, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Medical Group Pc | 9739191339 | 4 |
News Archive
The more exercise taken by individuals aged 65 years and older, the less likely biomarkers indicative of cardiac injury and new-onset heart failure are to increase, show US study findings.
Abnormal breast growth in young girls is linked to lavender oil exposure, according to a recent study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Patients who have received a solid organ transplant, such as kidney, liver, heart or lung, have an overall cancer risk that is double that of the general population, with an increased risk for many different types of malignancies, according to a study in the November 2 issue of JAMA.
MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.
› Verified 8 days ago
| Entity Name | Advanced Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710939798 PECOS PAC ID: 9739191339 Enrollment ID: O20060623000177 |
News Archive
The more exercise taken by individuals aged 65 years and older, the less likely biomarkers indicative of cardiac injury and new-onset heart failure are to increase, show US study findings.
Abnormal breast growth in young girls is linked to lavender oil exposure, according to a recent study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Patients who have received a solid organ transplant, such as kidney, liver, heart or lung, have an overall cancer risk that is double that of the general population, with an increased risk for many different types of malignancies, according to a study in the November 2 issue of JAMA.
MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Reuven Moshenyat, 2044 Ocean Ave, Suitea3, Brooklyn, NY 11230-7328 Ph: (718) 645-8901 | Dr Reuven Moshenyat, 2044 Ocean Ave, Suite A3, Brooklyn, NY 11230-7328 Ph: (718) 645-8901 |
News Archive
The more exercise taken by individuals aged 65 years and older, the less likely biomarkers indicative of cardiac injury and new-onset heart failure are to increase, show US study findings.
Abnormal breast growth in young girls is linked to lavender oil exposure, according to a recent study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Patients who have received a solid organ transplant, such as kidney, liver, heart or lung, have an overall cancer risk that is double that of the general population, with an increased risk for many different types of malignancies, according to a study in the November 2 issue of JAMA.
MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.
› Verified 8 days ago
Dr. Alexander Usorov, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 447 Atlantic Ave, Brooklyn, NY 11217 Phone: 718-858-6300 | |
Dr. Marcellus Andre Walker, MD Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 2094 Pitkin Ave, Brooklyn, NY 11207 Phone: 718-240-0516 Fax: 718-240-0564 | |
Lotus Ahmed, D.O Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 518 Mcdonald Ave, Brooklyn, NY 11218 Phone: 917-848-5432 Fax: 347-252-6754 | |
Mrs. Sophia Schwartzman, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2700 Ocean Avenue, Brooklyn, NY 11229 Phone: 518-587-1141 | |
Dr. Haitham M Ahmed, MD, MPH Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 101 Pennsylvania Avenue, Brooklyn, NY 11207 Phone: 718-240-2000 Fax: 718-240-2260 | |
Yanjin Yang, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-3000 | |
Ashwad Afzal, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-5246 |